VTCN1 and breast cancer: Iizuka and coworkers took advantage of a human PBMC-transplanted MHC class I- and class II–deficient NOG mice engrafted with BC cell lines to test the cytotoxic activity of a bispecific antibody targeting human CD3 and B7-H4, considered to be a negative regulator of immune responses.